Interpace Biosciences

Interpace Biosciences EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Interpace Biosciences (IDXG) as of Oct 17, 2026 is 4.08 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 8.11 M USD — a change of -49.63% (lower).

EBITDA

4.08 MUSD

YoY

-49.63%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Interpace Biosciences is 2025 4.08 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Interpace Biosciences was 2024 8.11 M USD. It decreases by -49.63% lower compared to the previous year.

The Interpace Biosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-8.26 M USD
Jan 1, 2019
-22.24 M USD
Jan 1, 2020
-21.10 M USD
Jan 1, 2021
-11.29 M USD
Jan 1, 2022
-2.54 M USD
Jan 1, 2023
4.82 M USD
Jan 1, 2024
8.11 M USD
Jan 1, 2025
4.08 M USD
The Interpace Biosciences EBITDA history
YEAREBITDAYoY
4.08 MUSD-49.63%
8.11 MUSD+68.08%
4.82 MUSD-289.92%
-2.54 MUSD-77.51%
-11.29 MUSD-46.48%
-21.10 MUSD-5.13%
-22.24 MUSD+169.38%
-8.26 MUSD+175.84%
-2.99 MUSD+13.29%
-2.64 MUSD-92.78%
-36.61 MUSD+188.93%
-12.67 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Interpace Biosciences Stock analysis

What does Interpace Biosciences do? Interpace Biosciences Inc., headquartered in Parsippany, New Jersey, develops and sells diagnostic clinical and pharma services. The company offers five commercialized molecular tests and one in clinical evaluation, including PancraGEN for pancreatic cancer diagnosis, PanDNA for a limited factor snapshot, ThyGeNEXT for thyroid cancer evaluation, ThyraMIR v2 for thyroid cancer diagnosis, and RespriDX to differentiate lung cancer origins. With 94 employees, it operates in the Health Care sector, focusing on molecular diagnostics and bioinformatics solutions for cancer risk assessment. Interpace Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interpace Biosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Interpace Biosciences is 4.08 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Interpace Biosciences changed from 8.11 M USD to 4.08 M USD, representing a -49.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Interpace Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Interpace Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Interpace Biosciences

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Interpace Biosciences